# ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation

- Link: https://www.thailand-business-news.com/pr-news/esmo-2026-mabwell-to-present-latest-clinical-data-on-nectin-4-targeting-adc-9mw2821-for-triple-negative-breast-cancer-in-oral-presentation
- Published: 2026-07-21T10:50:00+07:00
- Author: PR Newswire

SHANGHAI, July 21, 2026 /PRNewswire/ — Mabwell (688062.SH, 02493.HK), an innovation-
driven biopharmaceutical company with a fully integrated industry chain, will present
the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, 
for triple‑negative breast cancer in an oral presentation at the 2026 European Society
for Medical Oncology (ESMO) Annual Congress in Madrid, Spain, October 23-27, 2026.

Oral Presentation

Title: Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4-Directed Antibody-Drug Conjugate(
ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer(
la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (Topl)-Based ADCs: Results
from a Phase 2 Study.

Abstract No.: 4640RO

Presenter: Prof. ZHANG Jian, Chief Physician, Doctoral Supervisor (Fudan University
Shanghai Cancer Center)

Session: Breast cancer, advanced stage

Session Date and Time: 10/26/2026, 10:15 AM-11:45 AM (local time)

About Mabwell

Mabwell (688062.SH, 02493.HK) is an innovation-driven biopharmaceutical company 
with capabilities spanning the entire pharmaceutical value chain. The company is
committed to providing more effective and accessible therapies to meet global medical
needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is"
Explore Life, Benefit Health" and its vision is "Innovation, from Ideas to Reality."
For more information, please visit [www.mabwell.com/en](https://www.mabwell.com/en).

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited
to, the potential safety, efficacy, regulatory review or approval and commercial
success of our product candidates and those relating to the Company’s product development,
clinical studies, clinical and regulatory milestones and timelines, market opportunity,
competitive position, possible or assumed future results of operations, business
strategies, potential growth opportunities and other statements that are predictive
in nature. "Forward-looking statements" are statements that are not historical facts
and involve a number of risks and uncertainties, which may cause actual results 
to be materially different from any future results expressed or implied in the forward-
looking statements. These statements may be identified by the use of forward-looking
expressions, including, but not limited to, "expect," "anticipate," "intend," "plan,""
believe," "estimate," "potential," "predict," "project," "should," "would," and 
similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions.
Forward-looking statements are subject to a number of risks, uncertainties, and 
other factors, many of which are beyond the Company’s control, including, but not
limited to: environment; politic; economy; society; legislation; our dependence 
on our product candidates, most of which are still in preclinical or various stages
of clinical development; our reliance on third-party vendors, such as contract research
organizations and contract manufacturing organizations; the uncertainties inherent
in clinical testing; our ability to complete required clinical trials for our product
candidates and obtain approval from regulatory authorities for our product candidates;
our ability to protect our intellectual property; the loss of any executive officers
or key personnel. In case one or more of these risks or uncertainties deteriorate,
or any assumptions are incorrect, the actual results may be seriously inconsistent
with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-
looking statements, which speaks only as of the date of this press release. The 
Company disclaims any obligation, except as specifically required by law and the
rules of the applicable Stock authority to publicly update or revise any such statements
to reflect any change in expectations or in events, conditions, or circumstances
on which any such statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the forward-looking statements.
All forward-looking descriptions, figures and assumptions in this press release 
are applicable to this statement.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation ](http://www.prnasia.com/story/archive/5007818_CN07818_0?rand=184833)